FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype

被引:16
作者
Ferrara, Felicetto [1 ,2 ]
Criscuolo, Clelia [1 ,2 ]
Riccardi, Cira [1 ,2 ]
Izzo, Tiziana [1 ,2 ]
Pedata, Mariangela [1 ,2 ]
Copia, Carolina [1 ,2 ]
Vicari, Laura [3 ]
Tarsitano, Marina [3 ]
Palmieri, Salvatore [1 ,2 ]
Pane, Fabrizio [4 ,5 ]
机构
[1] Cardarelli Hosp, Div Hematol, Naples, Italy
[2] Cardarelli Hosp, Stem Cell Transplantat Unit, Naples, Italy
[3] Cardarelli Hosp, Med Genet Unit, Naples, Italy
[4] Univ Naples Federico II, Oncohematol Unit, Naples, Italy
[5] CEINGE, Biotecnol Avanzate, Naples, Italy
关键词
INTERNAL TANDEM DUPLICATIONS; ACUTE PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION SIGNATURE; MOLECULAR CHARACTERIZATION; CLINICAL IMPACT; AML; CYTOGENETICS; RELEVANCE; ADULT; OLDER;
D O I
10.1002/ajh.21458
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The clinical outcome of acute myelold leukemia (AML) is extremely variable, ranging from survival of a few days to cure [1-3]. In the recent years, different biological features at presentation have been reported as useful for the prediction of clinical outcome; in particular, nonrandom clonal chromosome aberrations, which are detectable in the leukemic cells of approximately 50% of adult AML patients, are not only diagnostic markers for specific AML subtypes but also provide prognostic Information for achievement of complete remission (CR), relapse risk, and survival [4-7]. Accordingly, pretreatment cytogenetics represent part of the routine diagnostics in patients with AML and the new World Health Organization classification of hematologic malignancies takes Into account specific chromosome aberrations and their molecular counterparts together with morphology, Immunophenotype, and clinical features [8]. Despite continuous Improvements In cytogenetic methodology, microscopically detectable chromosome abnormalities are not found in approximately 50% of AML patients and patients with normal karyotype are usually classified in the Intermediate-risk prognostic category [9,10]; In this AML patient subset, the clinical outcome Is very heterogeneous and 5-year survival rates vary between 25% and 45% in different studies. As a consequence, It is of utmost Importance to discriminate within this AML subgroup subjects with different prognostic characteristics at diagnosis [11-14].
引用
收藏
页码:532 / 535
页数:4
相关论文
共 41 条
  • [1] Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients
    Andersson, A
    Johansson, B
    Lassen, C
    Mitelman, F
    Billström, R
    Fioretos, T
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (05) : 307 - 313
  • [2] Age and acute myeloid leukemia
    Appelbaum, FR
    Gundacker, H
    Head, DR
    Slovak, ML
    Willman, CL
    Godwin, JE
    Anderson, JE
    Petersdorf, SH
    [J]. BLOOD, 2006, 107 (09) : 3481 - 3485
  • [3] Bacher U, 2005, HAEMATOLOGICA, V90, P1502
  • [4] Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia
    Baldus, Claudia D.
    Bullinger, Lars
    [J]. SEMINARS IN ONCOLOGY, 2008, 35 (04) : 356 - 364
  • [5] Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations:: a concise review
    Baldus, Claudia D.
    Mrozek, Krzysztof
    Marcucci, Guido
    Bloomfield, Clara D.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) : 387 - 400
  • [6] PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) : 620 - 625
  • [7] FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype
    Beran, M
    Luthra, R
    Kantarjian, H
    Estey, E
    [J]. LEUKEMIA RESEARCH, 2004, 28 (06) : 547 - 550
  • [8] Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients
    Breccia, Massimo
    Latagliata, Roberto
    Carmosino, Ida
    Guarini, Anna
    Diverio, Daniela
    De Cuia, Rosaria
    Cimino, Giuseppe
    Alimena, Giuliana
    [J]. LEUKEMIA & LYMPHOMA, 2008, 49 (05) : 994 - 997
  • [9] Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
    Buechner, Thomas
    Berdel, Wolfgang E.
    Haferlach, Claudia
    Haferlach, Torsten
    Schnittger, Susanne
    Mueller-Tidow, Carsten
    Braess, Jan
    Spiekermann, Karsten
    Kienast, Joachim
    Staib, Peter
    Grueneisen, Andreas
    Kern, Wolfgang
    Reichle, Albrecht
    Maschmeyer, Georg
    Aul, Carlo
    Lengfelder, Eva
    Sauerland, Maria-Cristina
    Heinecke, Achim
    Woermann, Bernhard
    Hiddemann, Wolfgang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) : 61 - 69
  • [10] An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML
    Bullinger, Lars
    Doehner, Konstanze
    Kranz, Raphael
    Stirner, Christoph
    Froeling, Stefan
    Scholl, Claudia
    Kim, Young H.
    Schlenk, Richard F.
    Tibshirani, Robert
    Doehner, Hartmut
    Pollack, Jonathan R.
    [J]. BLOOD, 2008, 111 (09) : 4490 - 4495